Skip to main content

Select Drug Profiles

Brintellix (Vortioxetine) Receives FDA Approval for the Treatment of Major Depressive Disorder

Injectafer (Ferric Carboxymaltose Injection) Receives FDA Approval for the Treatment of Iron-Deficiency Anemia

Practice Management

Insurance Companies’ Perspectives on the Orphan Drug Pipeline

Robert Handfield, PhD, Josh Feldstein, BA

Stakeholder Perspective

Breakthrough Therapy, or Breakthrough Pricing?

by Atheer A. Kaddis, PharmD

Practice Management

“Project IMPACT: Diabetes” Care Model Improves Health Outcomes in Underserved Populations in 25 Communities with a High Incidence of Diabetes

Benjamin M. Bluml, RPh

Practice Management

Cost and Drug Utilization Patterns Associated with the Management of Rosacea

Caroline Helwick

Practice Management, Pulmonary

Rehospitalization Is Driving Costs in Pulmonary Arterial Hypertension

Original Research

Pharmacy Staff Opinions Regarding Diabetic Retinopathy Screenings in the Community Setting: Findings from a Brief Survey

Miranda G. Law, BS, PharmD Candidate, Stephanie Komura, BS, PharmD Candidate, Ann P. Murchison, MD, MPH, Laura T. Pizzi, PharmD, MPH

Stakeholder Perspective

Screening for Diabetic Retinopathy in the Community Setting: Exploring the Options

by Gary M. Owens, MD

Practice Management

Modeling the Frequency and Costs Associated with Postsurgical Gastrointestinal Adverse Events for Tapentadol IR versus Oxycodone IR

Andrew Paris, MBA, Chris M. Kozma, PhD, Wing Chow, PharmD, MPH, Anisha M. Patel, MS, Samir H. Mody, PharmD, MBA, Myoung S. Kim, PhD, MBA

Stakeholder Perspective

Can Substituting Generic Drugs with Brand-Name Agents for Acute Pain Postsurgery Help to Deliver Cost-Effective, Quality Care?

by Matthew Mitchell, PharmD, MBA, FAMCP

Practicing Population Health

David B. Nash, MD, MBA

The Affordable Care Act Conundrum: Facing Reality in America’s Giant Social Experiment

Kip Piper, MA, FACHE

Page 161 of 244
Results 1601 - 1610 of 2434